Compare DSGR & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSGR | MPLT |
|---|---|---|
| Founded | 1952 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1995 | 2025 |
| Metric | DSGR | MPLT |
|---|---|---|
| Price | $34.76 | $13.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $35.00 | $32.67 |
| AVG Volume (30 Days) | 196.8K | ★ 571.1K |
| Earning Date | 04-30-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 212.50 | 82.39 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,980,023,000.00 | N/A |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $3.79 | N/A |
| P/E Ratio | $182.89 | ★ N/A |
| Revenue Growth | ★ 9.75 | N/A |
| 52 Week Low | $19.02 | $9.10 |
| 52 Week High | $35.06 | $40.43 |
| Indicator | DSGR | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 69.97 | 43.03 |
| Support Level | $34.54 | $10.67 |
| Resistance Level | $34.85 | $20.20 |
| Average True Range (ATR) | 0.10 | 0.97 |
| MACD | -0.16 | 0.84 |
| Stochastic Oscillator | 54.17 | 83.02 |
Distribution Solutions Group Inc is a specialty distribution company providing value-added distribution solutions to the maintenance, repair and operations (MRO), original equipment manufacturer (OEM) and industrial technology markets. The company operates through four reportable segments: Lawson, TestEquity, Gexpro Services and Canada Branch Division. Lawson distributes specialty products and services to the industrial, commercial, institutional and government MRO marketplace. TestEquity, which generates maximum revenue, distributes test and measurement equipment and solutions, industrial and electronic production supplies and vendor managed inventory programs. Gexpro Services is a supply chain solutions provider. The company generates majority of its revenue from United States.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.